Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP808910.RAhfdZpugJIGYs7NT8gXF0QcHdV07CD7qkbUG3K-lU3vA130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP808910.RAhfdZpugJIGYs7NT8gXF0QcHdV07CD7qkbUG3K-lU3vA130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP808910.RAhfdZpugJIGYs7NT8gXF0QcHdV07CD7qkbUG3K-lU3vA130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP808910.RAhfdZpugJIGYs7NT8gXF0QcHdV07CD7qkbUG3K-lU3vA130_provenance.
- befree-2016 importedOn "2016-02-19" NP808910.RAhfdZpugJIGYs7NT8gXF0QcHdV07CD7qkbUG3K-lU3vA130_provenance.
- NP808910.RAhfdZpugJIGYs7NT8gXF0QcHdV07CD7qkbUG3K-lU3vA130_assertion wasGeneratedBy ECO_0000203 NP808910.RAhfdZpugJIGYs7NT8gXF0QcHdV07CD7qkbUG3K-lU3vA130_provenance.
- NP808910.RAhfdZpugJIGYs7NT8gXF0QcHdV07CD7qkbUG3K-lU3vA130_assertion wasDerivedFrom befree-2016 NP808910.RAhfdZpugJIGYs7NT8gXF0QcHdV07CD7qkbUG3K-lU3vA130_provenance.
- NP808910.RAhfdZpugJIGYs7NT8gXF0QcHdV07CD7qkbUG3K-lU3vA130_assertion SIO_000772 20426708 NP808910.RAhfdZpugJIGYs7NT8gXF0QcHdV07CD7qkbUG3K-lU3vA130_provenance.
- NP808910.RAhfdZpugJIGYs7NT8gXF0QcHdV07CD7qkbUG3K-lU3vA130_assertion evidence source_evidence_literature NP808910.RAhfdZpugJIGYs7NT8gXF0QcHdV07CD7qkbUG3K-lU3vA130_provenance.
- NP808910.RAhfdZpugJIGYs7NT8gXF0QcHdV07CD7qkbUG3K-lU3vA130_assertion description "[Topical monoxidil and oral finasteride are commonly in use and have FDA approval for the treatment of male androgenetic alopecia; dutasteride, a type I and II 5-alpha-reductase inhibitor, is on hold in Phase III trials.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP808910.RAhfdZpugJIGYs7NT8gXF0QcHdV07CD7qkbUG3K-lU3vA130_provenance.